Byetta Gets Updated Warning Label Linked to Kidney Failure

Byetta, the Type-2 diabetes drug manufactured by Amylin Pharmaceuticals Inc., has received a stronger warning label from the FDA after the federal agency received updated information concerning the drug’s association with kidney problems relating to function and failure.
The side effects associated with Byetta include nausea, vomiting, and diarrhea. A loss or reduction in kidney function may result in a build-up of waste in the bloodstream which in turn can lead to serious infections and death.
The stronger warning label comes in the wake of 78 reports of kidney function issues in those taking Byetta.
Byetta (generic exenatide) is an injectable drug that is designed to help control blood sugar in patients with Type 2 diabetes. In 2008, the FDA said it planned to issue a stronger warning for Byetta after reports of 2 deaths and 4 hospitalizations linked to Byetta use.